Acrux (ASX:ACR) Reports A$20M Revenue and Announces US Product Launches
Financial Performance
Acrux has generated a total revenue of A$20 million over FY23 and FY24, supported by four marketed products in the US and eight contracted manufacturers for its generic portfolio.
Product Launches
The company announced the imminent launch of new products in the US market, including Dapsone 7.5% Gel and Nitroglycerin Ointment, expected in FY25. Additional products, such as Prilocaine/Lidocaine Cream and Dapsone 5% Gel, have already been launched.
Pipeline and Growth
Acrux is investing in eight pipeline products, aiming to add two new projects annually. This strategy is expected to drive revenue growth in FY25 and beyond, adding to its diversified portfolio targeting the US $21 billion topical pharmaceuticals market.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.